Prelude Therapeutics (PRLD) Revenue (2024 - 2026)

Prelude Therapeutics has reported Revenue for 3 years, with the latest figure at $4.6 million in Q1 2026.

• Quarterly Revenue changed N/A year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.7 million (changed N/A YoY) and the FY2025 annual result came in at $12.1 million, up 73.43% from the prior year.
• Revenue eased to $4.6 million in Q1 2026 per PRLD's latest filing, from $5.6 million in the prior quarter.
• Over five years, Revenue peaked at $6.5 million in Q3 2025 and troughed at $3.0 million in Q3 2024.
• A 3-year average of $4.7 million and a median of $4.6 million in 2026 frame the typical range for Revenue.
• The widest YoY moves for Revenue: up 116.67% in 2025, down 41.0% in 2025.
• Over 3 years, Revenue stood at $4.0 million in 2024, then jumped by 41.0% to $5.6 million in 2025, then declined by 18.79% to $4.6 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $4.6 million, $5.6 million, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.